22.06.2016 Views

Global Proteomics Market Analysis

Proteomics-Market-Size

Proteomics-Market-Size

SHOW MORE
SHOW LESS

Create successful ePaper yourself

Turn your PDF publications into a flip-book with our unique Google optimized e-Paper software.

<strong>Global</strong><br />

<strong>Proteomics</strong><br />

<strong>Market</strong> <strong>Analysis</strong><br />

June 2016<br />

Growth opportunities in a market in transition<br />

Growing demand for personalized medicine, and strong R&D<br />

investments in proteomics-based drug discovery projects has fueled<br />

the growth.


Executive Summary<br />

The global proteomics market has shown strong growth, and is<br />

expected to exceed $15 billion by 2020<br />

• <strong>Global</strong> market for <strong>Proteomics</strong> is forecast to exceed $15 billion by 2020,<br />

buoyed by growing demand for personalized medicine, and strong R&D<br />

investments in proteomics-based drug discovery projects.<br />

• Fueled by the importance of accurate and sensitive diagnosis offered by<br />

proteomics in the area of personalized medicine, the market for proteomics is<br />

expected to register strong growth in the coming years.<br />

• Detailed analysis of proteins provides better opportunities for the<br />

development of drugs that can target disease pathways more efficiently. The<br />

discovery of new protein biomarkers in disease development, and the<br />

corresponding development of novel drugs for cancer, cardiovascular, and<br />

neurodegenerative diseases have strengthened the market in recent years.<br />

Identification and characterization of proteins provides a deeper<br />

understanding of disease mechanisms when compared to genetic profiling.<br />

• Funding support offered by government and private organizations for<br />

proteomics research, developments in mass spectrometry-based proteomic<br />

and chemoproteomic strategies, and increased focus of biotechnology and<br />

pharmaceutical companies on novel drug discovery methods, bode well for<br />

the global proteomics market. Despite the opportunities for growth, the<br />

market will continue to face challenges such as tough regulatory approvals,<br />

dearth of qualified and skilled research manpower, and high cost of<br />

proteomics instruments and equipment.<br />

• The United States represents the largest market worldwide, followed by<br />

Europe. Emerging economies of Asia and Latin America are poised to fuel<br />

future growth in the market supported by socioeconomic growth, increased<br />

focus on biotechnological research, strong government support, and<br />

increased outsourcing of proteomics services to Asian countries.<br />

www.merkleandsears.com<br />

2014 2015 2016 2017 2018 2019 2020<br />

China<br />

Japan<br />

South Korea<br />

Taiwan<br />

India<br />

Australia<br />

Others<br />

<strong>Global</strong> proteomics market growth<br />

($ Billion)<br />

APAC proteomics market<br />

by Country (2015-2020)<br />

2


Executive Summary<br />

Strong growth curves ahead for many market segments<br />

• The US proteomics market benefits from the vast diversity and scale of<br />

operations of the academic sector. Further, ability of academics to reposition<br />

themselves into new groups in order to meet the scientific challenges in<br />

proteomics industry also proves beneficial for the industry. <strong>Proteomics</strong><br />

research, being complementary to genomic approaches, has been<br />

witnessing increased integration with drug discovery market. Rising interest<br />

in integrated technologies is driving rapid expansion of bio-informatics and<br />

protein biochip technologies in Europe.<br />

• The shift towards proteomics from genomics facilitates technological<br />

advancements, which are aimed at providing assistance to drug discovery<br />

researchers by offering enhanced throughput, resolution, and sensitivity,<br />

compared to conventional protein research tools.<br />

• Over the next decade, better understanding of proteome will lead to the<br />

development of advanced sequencing methods and superior technologies<br />

that help expand application possibilities.<br />

• Discovery of new biomarkers is expected to enable successful development<br />

of newer drugs. Technological improvements in instruments and workflow<br />

and miniaturization of biochip devices will create new milestones in diagnosis<br />

and drug development applications. Biomarker-based research will be a<br />

strong area of focus given the increasing importance of proteomics in novel<br />

drug discovery, design, and development.<br />

• Major players covered in the report include Bio-Rad Laboratories Inc.,<br />

ThermoFisher Scientific, Waters Corporation, Sigma-Aldrich Corporation,<br />

PerkinElmer Inc., Bruker Daltonics Inc., Caprion <strong>Proteomics</strong> Inc., GE<br />

Healthcare, and Shimadzu Biotech, among others.<br />

www.merkleandsears.com<br />

U.S.<br />

Canada<br />

Mexico<br />

Rest of<br />

North<br />

America<br />

North American proteomics market<br />

by application<br />

Aggregate<br />

2020 demand<br />

<strong>Market</strong> share breakdown, 2015<br />

xx%<br />

xx%<br />

xx<br />

xx<br />

xx<br />

xx<br />

Demand<br />

growth<br />

%, CAGR<br />

xx<br />

xx<br />

xx<br />

xx<br />

xx<br />

xx<br />

xx<br />

xx<br />

xx%<br />

3


<strong>Market</strong> <strong>Analysis</strong><br />

Two-dimensional electrophoresis continues to hog the limelight<br />

• Two-dimensional electrophoresis (2DE) is one of the most cost-effective protein<br />

profiling technologies. Using this technology, the constituents of a protein<br />

sample can be entirely visualized in a single gel.<br />

• The global economic recession affected the government research spending<br />

across the globe. However, it was a blessing in disguise for the 2DE industry as<br />

researchers were on the prowl for cheaper technologies in that cash-crunched<br />

climate. Participants in the market capitalized on the then prevailing situation to<br />

improve their revenues.<br />

• The 2DE market is projected to grow at very high rate in the near term, as<br />

academic researchers – the main consumers of these products – are<br />

increasingly investing more in cheaper alternatives for protein expression<br />

studies, such as 2DE. End users are more likely to automate their existing<br />

2DGE-MS process than invest in new technologies since the others have not<br />

been as successful on a wide range of samples.<br />

• Sample preparation solutions can vary dramatically from each other. Companies<br />

therefore find it very difficult to come out with sample preparation kits that will<br />

effectively address the varied needs of the market. A large number of products<br />

are required to address this market, but each of these products will enjoy only a<br />

limited response due to the differing needs of customers. Sample preparation is<br />

a major challenge that the industry needs to overcome. It affects both the<br />

reproducibility and the resolution of the 2DE experiment which, in turn,<br />

influences the end results.<br />

• As a result, many market players are increasingly focusing on determining the<br />

kinds of samples that are the most widely studied in the market. Following this, a<br />

feasibility analysis to check the financial viability of developing a sample<br />

preparation kit for such samples is conducted. This has helped these companies<br />

to more effectively fulfil varied sample requirements.<br />

www.merkleandsears.com<br />

C a p a c i t y<br />

Steep growth curve ahead for<br />

the market<br />

Current market<br />

position<br />

xx%<br />

xx%<br />

2016<br />

<strong>Market</strong> share breakdown, 2015<br />

Predicted strategic<br />

inflection point<br />

xx%<br />

4<br />

Time


<strong>Market</strong> <strong>Analysis</strong><br />

Growing adoption of integrated Liquid Chromatography systems<br />

• Increasing need to extract greater amounts of proteomic information is driving<br />

the adoption of Liquid Chromatography (LC). Interest and level of activity in<br />

the field of proteomics has remained high and will continue to increase<br />

because crucial information is mostly gathered from proteins.<br />

• Researchers are still on the lookout for the product that will enable them to<br />

draw information accurately and efficiently. As the study of proteins gains<br />

importance in other industries and research markets, the demand for protein<br />

LC technologies is expected to continue growing.<br />

• The superior capabilities of LC to analyze complex samples when coupled<br />

with mass spectrometry (MS) are propelling deployment of integrated LC<br />

systems.<br />

• Manufacturers, recognizing the needs of researchers working on advanced<br />

analysis, are striving to offer technologies such as fully integrated LC-MS<br />

systems.<br />

• These integrated solution systems are likely to provide researchers with<br />

sophisticated analysis tools offering higher ease of use. Sustained innovation<br />

is anticipated to further increase LC adoption.<br />

• However, limited volume of protein samples has restricted the number of LC<br />

experiments conducted so far. In many proteomics research programs,<br />

protein sample availability restricts liquid chromatography (LC) experiments.<br />

• Researchers are often unable to conduct the entire range of experiments<br />

desired since only small amounts of valuable protein samples are available.<br />

Answering numerous questions with limited sample is difficult. Moreover, with<br />

researchers often having to prioritize experiments, researchers are unable to<br />

conduct thorough studies.<br />

www.merkleandsears.com<br />

<strong>Global</strong> liquid chromatography market for<br />

protein studies<br />

$ Million<br />

2014 2015 2016 2017 2018 2019 2020<br />

<strong>Market</strong> share breakdown, 2015<br />

xx%<br />

xx%<br />

xx%<br />

5


<strong>Market</strong> <strong>Analysis</strong><br />

Growing need for automated crystallization shaping the protein<br />

crystallography market<br />

• Increasing demand for high throughput protein crystallography has resulted<br />

increase in adoption of automated crystallization. The need to understand<br />

exactly how small molecules bind to their protein target is driving the demand for<br />

protein crystallography in drug discovery. A higher throughput protein<br />

crystallography process requires protein crystallization to also become high<br />

throughput and this is best achieved through automated crystallization. A<br />

number of large proteomic initiatives are being launched, increasing market<br />

opportunities for automated crystallization.<br />

• Drug discovery initiatives have driven numerous technological advancements in<br />

structural proteomics. Pharmaceutical companies today acknowledge that<br />

structure discovery helps lead optimization. With rapid technology advances,<br />

structure-based design is set to become a preferred method for discovering new<br />

drugs.<br />

• As an increasing number of companies discover the importance and significance<br />

of protein structure studies for drug discovery, more efforts are being made<br />

toward improving structural determination technologies. <strong>Market</strong> consolidation<br />

and industrialization along with the introduction of powerful integrated systems is<br />

changing research approaches. Besides automation, miniaturization of protein<br />

crystals and processes including purification is another big trend.<br />

• Lack of experienced researchers has further fueled the demand for automated<br />

crystallization. Protein crystallization is a process that requires training, skill, and<br />

time. The number of trained researchers and people willing to commit to such a<br />

process has been decreasing. The surge in automation has addressed the<br />

worrisome dearth of protein-structure researchers. However, automation allows<br />

researchers with less experience and training to be involved in crystallization.<br />

This frees researchers, allowing them to focus on increasing productivity,<br />

reproducibility, and throughput.<br />

www.merkleandsears.com<br />

C a p a c i t y<br />

Steep growth curve ahead for<br />

the market<br />

Current market<br />

position<br />

xx%<br />

xx%<br />

2016<br />

<strong>Market</strong> share breakdown, 2015<br />

Predicted strategic<br />

inflection point<br />

xx%<br />

6<br />

Time


Industry <strong>Analysis</strong><br />

<strong>Global</strong> Industry Overview<br />

• Proteomic research inherently requires huge capital investments and<br />

historically, it has yielded poor revenues. Pharmaceutical companies have<br />

hesitated in adopting the proteomics technologies in their drug<br />

development pipeline as they have been wary of premium pricing.<br />

• However, today public funding institutions are giving importance to this<br />

growing biological discipline next to comparative genomics. The proteomics<br />

market is considered an emerging area with immense potential. In fact,<br />

Governments and federal ministries in three major European countries,<br />

namely the United Kingdom, France and Germany, have allocated thematic<br />

priorities to nurture the growth of this market. This has resulted in greater<br />

industrialization of this field, which in turn, has boosted the confidence of<br />

companies to invest in this fast-paced and dynamic arena. Low return on<br />

investment that can dissuade potential entrants in proteomics technology<br />

markets has thus been offset by increasing public funding.<br />

• The increasing relevance of protein-protein interactions and protein<br />

analytics in drug discovery as well as clinical diagnostics has highlighted<br />

the importance of proteome research. Technological advancements in<br />

protein separation technologies and two-dimensional gel electrophoresis<br />

are likely to usher in a ubiquitous approach to assess differential protein<br />

expressions. Maximum utility of expression proteomics tools in the target<br />

discovery phase of drug development is likely to trigger reliable separation<br />

and identification of low abundant proteins with poor expression levels.<br />

Moreover, the development of matrix-assisted laser desorption/ionization<br />

(MALDI) and electrospray ionization (ESI) technologies has enlarged the<br />

scope of building versatile mass spectrometers, considered the cornerstone<br />

of proteomics. The improved mass spectrometers are likely to have<br />

enhanced functionalities of automation and compatibility with other<br />

proteomics equipment.<br />

www.merkleandsears.com<br />

<strong>Global</strong> proteomics market<br />

$ Million<br />

2014 2015 2016 2017 2018 2019 2020<br />

<strong>Market</strong> share breakdown, 2015<br />

xx%<br />

xx%<br />

xx%<br />

7


Regional <strong>Analysis</strong><br />

European proteomics market overview<br />

• The European Union (EU) has become a popular hub for advanced research<br />

into proteomics. This can be attributed to the significant government funding at<br />

both the national level and from individual EU agencies.<br />

• Moreover, Europe houses some of the largest pharmaceutical companies that<br />

are extending their support to research programs related to proteomics, either<br />

in-house or in collaboration with smaller firms. The primary goal of most of<br />

these pharmaceutical companies is to go beyond the realms of human genome<br />

sequencing and expand the list of identified proteins and genes, which will<br />

ultimately aid in understanding disease mechanisms and developing<br />

corresponding therapeutics.<br />

• The high impact of emerging technologies such as proteomics is causing<br />

radical changes in the fields of drug discovery as well as clinical research and<br />

diagnostics. As a result, end users in the European life sciences arena are<br />

looking for a complete, integrated solution. The current trend in the European<br />

market has been the formation of broad partnerships, as the European<br />

commercial sector realizes that this is one of the best ways of maximizing<br />

opportunities in this area since smaller companies can affiliate themselves with<br />

larger, more recognized suppliers.<br />

• Increased funding for research and sustained pharmaceutical and<br />

biotechnology industry interest in drug discovery is a major growth factor for the<br />

European proteomics market. Though proteomics is a critical technology for<br />

mass screening and post-translational modification of proteins, the European<br />

proteomics industry's progress is restricted by complications faced by<br />

organizations in sourcing adequate funding for various research initiatives. The<br />

relative higher cost of equipment and software in the European market has<br />

enhanced the importance of funding to huge extent.<br />

www.merkleandsears.com<br />

European proteomics market<br />

$ Million<br />

2014 2015 2016 2017 2018 2019 2020<br />

<strong>Market</strong> share breakdown, 2015<br />

xx%<br />

xx%<br />

xx%<br />

8


Country <strong>Analysis</strong><br />

Government support has fueled the growth in Australian market<br />

• Growing focus on research has driven the growth in proteomics market in<br />

Australia. Extensive research in proteomics is promising cures for previously<br />

untreatable diseases. With the Government assisting by providing additional<br />

tax concessions, the spending on research and development (R&D) is likely to<br />

increase by 58.0 percent in 2016.<br />

• As a result, more than 300 biotechnology companies focusing on proteomics<br />

applications have set up operations in Australia to take advantage of this<br />

favorable environment. Drug discovery companies are also likely to have ample<br />

opportunities to slightly modify the lead compound in order to screen and<br />

exclude patients of a certain genotype who are more prone to developing<br />

certain side effects from clinical trials.<br />

• Australian research companies are increasingly entering into collaborations<br />

with Venture Capitalists for funds. Compared to Western countries, most of the<br />

Australian biotech companies are start-up undertakings that are in need of<br />

capital to support their research.<br />

• However, venture capitalists (VCs) have been hesitant to provide funds since<br />

these companies have few products in the final stages of drug discovery and<br />

have to wait for around ten years for their products to complete clinical trials<br />

before releasing them into the market.<br />

• The long gestation period and the low market awareness on the potential of<br />

biotech products have led to insufficient funding of the biotech ventures in<br />

Australia as investors perceive them as being too risky. However, the Australian<br />

government and the top research companies have helped the VCs to<br />

understand the commercial viability of their projects and the time required to<br />

market them. Their efforts have begun to bore fruits as the market has<br />

witnessed growing entries from several major international VCs in the recent<br />

years.<br />

www.merkleandsears.com<br />

VC funding in Australian proteomics market<br />

$ Million<br />

2014 2015 2016 2017 2018 2019 2020<br />

<strong>Market</strong> share breakdown, 2015<br />

xx%<br />

xx%<br />

xx%<br />

9


Growing Diabetic Population – A Key Growth Driver<br />

Prevalence of Diabetes in Million (2005 – 2015)<br />

Growing base of diabetic population and the acute need for their quality care and<br />

treatment is boosting the adoption of proteomics technologies in the stem cell research activities<br />

Million Million Million<br />

30<br />

25<br />

25<br />

25<br />

20<br />

15<br />

10<br />

5<br />

0<br />

20<br />

15<br />

10<br />

5<br />

0<br />

20<br />

15<br />

10<br />

5<br />

0<br />

U.S.<br />

Canada<br />

Brazil Mexico Argentina<br />

Peru Venezuela Chile<br />

Russia Turkey Poland<br />

Czech Republic<br />

Hungary<br />

Million<br />

25<br />

20<br />

15<br />

10<br />

5<br />

0<br />

2005 2006 2007 2008 2009 2010 2011 2012 2013 2014 2015<br />

Million<br />

140<br />

Belgium<br />

Netherlands 120<br />

Sweden 100<br />

Switzerland<br />

Portugal<br />

80<br />

Austria 60<br />

U.K<br />

Spain<br />

40<br />

France 20<br />

Italy<br />

0<br />

Germany<br />

2005 2006 2007 2008 2009 2010 2011 2012 2013 2014 2015<br />

www.merkleandsears.com<br />

New Zealand<br />

Hong Kong<br />

Taiwan<br />

Thailand<br />

Philippines<br />

Australia<br />

Malaysia<br />

Indonesia<br />

South Korea<br />

Japan<br />

China<br />

India<br />

10


Competition <strong>Analysis</strong><br />

Fourteen players identified as candidates for benchmarking as<br />

'Large Competition' given industry spread<br />

Frequency across market segments<br />

6<br />

xxxx<br />

xxxx<br />

xxxx<br />

4<br />

xxxx<br />

xxxx<br />

xxxx<br />

xxxx<br />

xxxx<br />

2<br />

xxxx<br />

xxxx<br />

xxxx<br />

xxxx<br />

0<br />

xxxx<br />

xxxx<br />

(2)<br />

Prominent players<br />

Emerging players<br />

(4)<br />

0 1 2 3 4 5 6<br />

Frequency across Regions<br />

Fourteen players defining the industry<br />

benchmark in 2015<br />

www.merkleandsears.com<br />

11


Thank you<br />

www.merkleandsears.com

Hooray! Your file is uploaded and ready to be published.

Saved successfully!

Ooh no, something went wrong!